|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/12/22 Arcadia Biosciences, Inc. 10-Q 3/31/22 82:11M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 838K
2: EX-10.1 Material Contract HTML 40K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
12: R1 Document and Entity Information HTML 78K
13: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 139K
14: R3 Condensed Consolidated Balance Sheets HTML 35K
(Parenthetical) (Unaudited)
15: R4 Condensed Consolidated Statements of Operations HTML 120K
and Comprehensive (Loss) Income (Unaudited)
16: R5 Condensed Consolidated Statements of Stockholders' HTML 101K
Equity (Unaudited)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 133K
(Unaudited)
18: R7 Description of Business and Basis of Presentation HTML 46K
19: R8 Recent Accounting Pronouncements HTML 46K
20: R9 Inventory HTML 47K
21: R10 Property and Equipment, Net HTML 71K
22: R11 Investments and Fair Value Instruments HTML 214K
23: R12 Arcadia Wellness Acquisition HTML 91K
24: R13 Intangible Assets, Net HTML 134K
25: R14 Consolidated Joint Venture HTML 32K
26: R15 Collaborative Arrangements HTML 29K
27: R16 Leases HTML 100K
28: R17 Equity Financing HTML 68K
29: R18 Warrants HTML 256K
30: R19 Stock-Based Compensation and Employee Stock HTML 122K
Purchase Program
31: R20 Income Taxes HTML 34K
32: R21 Commitment and Contingencies HTML 47K
33: R22 Net (Loss) Income per Share HTML 85K
34: R23 Related-Party Transactions HTML 36K
35: R24 Subsequent Events HTML 26K
36: R25 Description of Business and Basis of Presentation HTML 48K
(Policies)
37: R26 Inventory (Tables) HTML 44K
38: R27 Property and Equipment, Net (Tables) HTML 62K
39: R28 Investments and Fair Value Instruments (Tables) HTML 213K
40: R29 Arcadia Wellness Acquisition (Tables) HTML 77K
41: R30 Intangible Assets, Net (Tables) HTML 134K
42: R31 Leases (Tables) HTML 95K
43: R32 Warrants (Tables) HTML 257K
44: R33 Stock-Based Compensation and Employee Stock HTML 94K
Purchase Program (Tables)
45: R34 Net Loss per Share (Tables) HTML 84K
46: R35 Description of Business and Basis of Presentation HTML 55K
- Additional Information (Detail)
47: R36 Recent Accounting Pronouncements - Additional HTML 66K
Information (Detail)
48: R37 Inventory - Additional Information (Detail) HTML 25K
49: R38 Inventory - Summary of Inventories (Detail) HTML 30K
50: R39 Property and Equipment, Net - Summary of Property HTML 46K
and Equipment, Net (Detail)
51: R40 Property and Equipment, Net - Additional HTML 40K
Information (Detail)
52: R41 Investments and Fair Value Instruments - Summary HTML 31K
of Amortized Cost and Fair Value of Investment
Securities Portfolio (Detail)
53: R42 Investments and Fair Value Instruments - HTML 26K
Additional Information (Detail)
54: R43 Investments and Fair Value Instruments - Summary HTML 32K
of Fair Value of Investments Securities (Detail)
55: R44 Investments and Fair Value Instruments - Summary HTML 53K
of Changes in Fair Value and Other Adjustments of
Liabilities (Detail)
56: R45 Industrial Seed Innovations Acquisition - HTML 52K
Additional Information (Detail)
57: R46 Arcadia Wellness Acquisition - Additional HTML 88K
Information (Detail)
58: R47 Arcadia Wellness Acquisition - Schedule of HTML 45K
Allocation Purchase Price of Assets Acquired at
Fair Value at Acquisition Date (Detail)
59: R48 Arcadia Wellness Acquisition - Schedule of HTML 37K
Unaudited Pro-forma Condensed Consolidated Results
of Operations (Detail)
60: R49 Intangible Assets, Net - Schedule of Intangible HTML 47K
Assets, Net (Detail)
61: R50 Intangible Assets, Net - Schedule of Intangible HTML 26K
Assets, Net (Parenthetical) (Detail)
62: R51 Intangible Assets, Net - Additional Information HTML 30K
(Detail)
63: R52 Intangible Assets, Net - Schedule of Future HTML 39K
Amortization of Intellectual Property and Customer
Lists (Detail)
64: R53 Consolidated Joint Venture - Additional HTML 40K
Information (Detail)
65: R54 Collaborative Arrangements - Additional HTML 27K
Information (Detail)
66: R55 Leases - Additional Information (Detail) HTML 33K
67: R56 Leases - Schedule of Leases (Detail) HTML 57K
68: R57 Equity Financing - Additional Information (Detail) HTML 142K
69: R58 Warrants - Summary of Warrants Issued to Purchase HTML 98K
Common Stock (Detail)
70: R59 Warrants - Summary of Warrants Issued to Purchase HTML 29K
Common Stock (Parenthetical) (Detail)
71: R60 Stock-Based Compensation and Employee Stock HTML 99K
Purchase Program - Additional Information (Detail)
72: R61 Stock-Based Compensation and Employee Stock HTML 57K
Purchase Program - Summary of Activity Under Stock
Incentive Plans (Detail)
73: R62 Stock-Based Compensation and Employee Stock HTML 33K
Purchase Program - Weighted-Average Fair Value
Assumption of Stock Option Awards (Detail)
74: R63 Income Taxes - Additional Information (Detail) HTML 30K
75: R64 Commitments and Contingencies - Additional HTML 70K
Information (Detail)
76: R65 Net (Loss) Income per Share - Summary of HTML 60K
Computation of Basic and Diluted Net Income Per
Common Share (Detail)
77: R66 Related-Party Transactions - Additional HTML 49K
Information (Detail)
80: XML IDEA XML File -- Filing Summary XML 149K
78: XML XBRL Instance -- rkda-20220331_htm XML 2.81M
79: EXCEL IDEA Workbook of Financial Reports XLSX 97K
8: EX-101.CAL XBRL Calculations -- rkda-20220331_cal XML 190K
9: EX-101.DEF XBRL Definitions -- rkda-20220331_def XML 917K
11: EX-101.LAB XBRL Labels -- rkda-20220331_lab XML 1.55M
10: EX-101.PRE XBRL Presentations -- rkda-20220331_pre XML 1.20M
7: EX-101.SCH XBRL Schema -- rkda-20220331 XSD 224K
81: JSON XBRL Instance as JSON Data -- MetaLinks 460± 703K
82: ZIP XBRL Zipped Folder -- 0000950170-22-009747-xbrl Zip 246K
| EX-10.1 |
Exhibit 10.1
[***Address Redacted***]
Dear Stan:
On behalf of Arcadia Biosciences, Inc., henceforth the “Company,” it is my pleasure to offer you the position of Chief Executive Officer. This letter constitutes the entire agreement relating to the terms of your employment, except for the Confidentiality and Invention Assignment Agreement between you and the Company (which must be executed as a condition of your employment), and the Severance and Change in Control Agreement between you and the Company, to be dated the Effective Date. The terms set forth below shall be effective as of your date of hire, which is anticipated to be 2/2/2022 (the “Effective Date”), conditioned upon such approval.
Title and Base Salary. Your title will be Chief Executive Officer and you will report directly to the Company’s Board of Directors. As of the Effective Date, your annual base salary shall be $350,000. The salary shall be subject to an annual review and may be increased at the Board’s discretion.
Bonus Compensation. In addition to your base salary, you will be eligible for an annual incentive cash bonus, as determined by the Company. Your annual incentive cash bonus shall have a target equal to 50% of your base salary as of the Effective Date, prorated for the portion of year during which you are employed by the Company. The target bonus and its components, the Company performance goals, and your individual objectives shall be determined and documented each year by the Compensation Committee of the Board of Directors (the “Compensation Committee”).
Vacation. You will be entitled to four (4) weeks of paid vacation for each calendar year.
Equity Awards.
Initial Grant
Concurrent with the commencement of your employment with the Company, you will be granted an option to purchase shares of common stock of the Company (“Company
202 Cousteau Place ź Suite 105 ź Davis, CA 95618 ź Tel: 530-756-7077ź Fax: 530-756-7027 ź Web: www.arcadiabio.com
Common Stock”) as follows, under the terms and conditions of a Non-Qualified Stock Option Agreement (an “Option”):
Strike Price* |
Number of Shares |
FMV |
Number of shares that would make the black-scholes value equal $250,000 |
* FMV = the price of a share of RKDA common stock at close of market on the date of grant, which will be the Effective Date; if FMV is greater than the listed strike price on the date of grant, such strike price shall
be increased to reflect FMV.
Your Option shall vest and become exercisable in accordance with the schedule below:
Other Grants
The Company may grant equity awards to you from time to time, which will be subject to the terms of the applicable equity compensation plan or arrangement in effect at the time of grant. The Compensation Committee will determine in its discretion whether you will be granted any such equity awards and the terms and conditions of any such awards in accordance with the terms of any applicable equity plan. You should be aware that you may incur federal and state income taxes as a result of your receipt, or the vesting of any equity compensation awards, and it shall be your responsibility to pay any such applicable taxes.
Severance and Change in Control Agreement. You will have the benefits set forth in a Severance and Change in Control Agreement between you and the Company to be executed on the Effective Date, a copy of which is attached hereto.
Other Benefits. You will be eligible for all Company adopted benefits, under the terms and conditions of such benefit plans. Your coverage for medical, dental, and vision benefits will become effective on the first of the month following your first thirty (30) days of employment. You will also be given an additional $5,000 each year for health and wellness to use at your discretion. Such benefit does not constitute a Company wellness plan.
202 Cousteau Place ź Suite 105 ź Davis, CA 95618 ź Tel: 530-756-7077ź Fax: 530-756-7027 ź Web: www.arcadiabio.com
Your employment is “at-will,” which means that either you or the Company may terminate the employment relationship at any time for any reason or for no reason (subject to the terms of the Severance and Change in Control Agreement). This at-will relationship may not be modified by any oral or implied agreement.
Conditions of Employment.
The information contained in this letter represents the entire substance of Arcadia’s offer of employment to you and is contingent upon successful completion of all pre-and post-employment checks. If all the above terms and conditions meet with your approval, please sign this letter, and return it by January 31, 2022. If this document is not returned by this date, this offer of employment shall be withdrawn.
I very much look forward to you joining the Arcadia team. If you should have any questions, please feel free to call me.
Sincerely,
/s/ KEVIN COMCOWICH
Interim Chief Executive Officer
ACCEPTED BY:
/s/ STAN JACOT
Date
202 Cousteau Place ź Suite 105 ź Davis, CA 95618 ź Tel: 530-756-7077ź Fax: 530-756-7027 ź Web: www.arcadiabio.com
202 Cousteau Place ź Suite 105 ź Davis, CA 95618 ź Tel: 530-756-7077ź Fax: 530-756-7027 ź Web: www.arcadiabio.com
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 1/31/26 | ||||
| 2/28/23 | ||||
| Filed on: | 5/12/22 | 8-K, EFFECT | ||
| For Period end: | 3/31/22 | 10-K | ||
| 1/31/22 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/24 Arcadia Biosciences, Inc. 10-K/A 12/31/23 10:1.4M Donnelley … Solutions/FA 3/28/24 Arcadia Biosciences, Inc. 10-K 12/31/23 102:14M Donnelley … Solutions/FA 4/13/23 Arcadia Biosciences, Inc. 10-K/A 12/31/22 12:2M Donnelley … Solutions/FA 3/30/23 Arcadia Biosciences, Inc. 10-K 12/31/22 110:18M Donnelley … Solutions/FA 10/07/22 Arcadia Biosciences, Inc. 424B3 1:222K Donnelley … Solutions/FA 9/27/22 Arcadia Biosciences, Inc. S-1 6:672K ActiveDisclosure/FA 8/16/22 Arcadia Biosciences, Inc. 424B5 1:447K Donnelley … Solutions/FA 5/31/22 Arcadia Biosciences, Inc. S-8 5/31/22 4:161K ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/07/22 Arcadia Biosciences, Inc. 8-K:5,9 2/02/22 13:619K Donnelley … Solutions/FA |